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2Current ACIP Recommendations for Tdap and Td in 
adolescents and adults in the United States
 Single dose of Tdap:  Persons aged ≥11 years 
–
–
–
–
–
–
–
Preferably at aged 11-12 years
 Booster dose of Td every 10 years
Single Tdap can replace decennial Td booster dose
Dose administered regardless of interval since last Td vaccine
5 years if needed for tetanus prophylaxis for wound management
 Catch-up immunization
3-dose series: Single dose for Tdap (preferably the first dose), 2 doses of Td
 Tdap during every pregnancy (no proposed change)
No interval between repeat Tdap doses
Off label recommendation
Liang JL, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. 
3Consider the evidence for a potential policy change to allow either Td or Tdap 
vaccine to be used in situations where only Td vaccine is currently 
recommended for: 
1) Decennial Td booster in adults 
2) Tetanus prophylaxis as needed for wound management
3) Catch-up immunization schedule
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4Policy options for ACIP consideration
Policy question Work Group Interpretation
Either Td or Tdap can be used for the decennial Td 
booster We are in favor of the intervention
Either Td or Tdap can be used for tetanus prophylaxis in 
the setting of wound prophylaxis We are in favor of the intervention
Either Td or Tdap can be used for additional doses of the 
catch-up immunization schedule for persons ≥7 years We are in favor of the intervention
5Safety of closely spaced Tdap vaccines in the catch-up immunization schedule 
Dr. Pedro Moro, Immunization Safety Office
Tdap an–
–
d Td: Summary of work group considerations and policy options 
Dr. Fiona Havers, Pertussis Vaccines Work Group Lead 
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6Next steps
 Evaluate the spacing of booster doses for continued protection against 
tetanus and diphtheria
–
–
–
Duration of protection
Some countries don’t give Td boosters
Other countries give Td booster doses less frequently than every 10 
years 
 Work Group will evaluate evidence regarding whether the current 10-
year interval between Td booster doses should be changed 
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For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
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